During 2012, the Chilean Antitrust case denominated “Pharmacies” became one of the leading in terms of investigation conducted by the Fiscalia Nacional Economica and one of the highlighted decisions of the Antitrust Court, Tribunal de Defensa de la Libre Competencia. This paper analyses the basic structure of judgement 119/2012 issued by the Tribunal, and confirmed by Chilean Supreme Court, by decision 2578-2012, which it was written by judge Sergio Muñoz, rejecting an appeal issued by Cruz Verde S.A and Salcobrand S.A. The article also studies the way by which the judges define the relevant market, and discusses some elements about parallel pricing. Furthermore, the case was controversial with respect to to the application of an agreement of conciliation with FASA S.A.
Full Content: SSRN
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Big Tech Braces for Potential Changes Under a Second Trump Presidency
Nov 6, 2024 by
CPI
Trump’s Potential Shift in US Antitrust Policy Raises Questions for Big Tech and Mergers
Nov 6, 2024 by
CPI
EU Set to Fine Apple in First Major Enforcement of Digital Markets Act
Nov 5, 2024 by
CPI
Six Indicted in Federal Bid-Rigging Schemes Involving Government IT Contracts
Nov 5, 2024 by
CPI
Ireland Secures First €3 Billion Apple Tax Payment, Boosting Exchequer Funds
Nov 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI